reports
Five Directors sold after exercising options/sold 728,187 shares at 11...
Five Directors at Sciclone Pharmaceuticals Inc sold after exercising options/sold 728,187 shares at 11.180USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the c...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SciC...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky, LLP has filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of current stockholders of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ:SCLN) in connection with the planned acquisition of the company by affiliates of GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partners, and Boying Investments Limited (the “Consortium”). On June 8, 2017...
INVESTOR ALERT: Brower Piven Commences an Investigation into the Propo...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) (“SciClone” or the “Company”) relating to the proposed buyout of SciClone by a consortium consisting of entities affiliated with GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partner...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investig...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) stock prior to June 8, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of SciClone to a consortium led by GL Capital Management GP Limited for $11.18 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/SCLN-Info-Request...
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Pr...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) (“SciClone” or the “Company”) relating to the proposed buyout of SciClone by a consortium consisting of entities affiliated with GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partner...
SCICLONE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P....
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of SciClone Pharmaceuticals, Inc. (NASDAQ GS: SCLN)? Did you purchase any of your shares prior to June 8, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ GS...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) stock prior to June 8, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of SciClone to a consortium led by GL Capital Management GP Limited for $11.18 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/SCLN-Info-Request...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.